|
시장보고서
상품코드
2088699
면역조직화학 시장 : 제품 카테고리, 기술, 검체 유형, 용도, 적응증, 최종 사용자별 - 세계 시장 예측(2026-2032년)Immunohistochemistry Market by Product Category, Technology, Specimen Type, Application, Indication, End User - Global Forecast 2026-2032 |
||||||
360iResearch
면역조직화학 시장은 2032년까지 연평균 복합 성장률(CAGR) 6.16%로 성장해 50억 7,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도(2025년) | 33억 3,000만 달러 |
| 추정 연도(2026년) | 35억 3,000만 달러 |
| 예측 연도(2032년) | 50억 7,000만 달러 |
| CAGR(%) | 6.16% |
면역조직화학(IHC)은 보존된 세포 구조 내의 단백질 발현을 확인할 수 있기 때문에 조직 기반 진단, 중개 연구 및 정밀 종양학 분야에서 여전히 핵심 기술로 자리 잡고 있습니다. 일상적인 병리 검사에서 IHC는 종양 분류, 바이오마커 확인, 감염증 평가, 자가면역 병리 및 치료법 선택을 지원하며, 병원 검사실, 참조 검사 기관, 제약 개발 기업 및 위탁 연구 기관에 있어 필수적인 기술로 자리 잡고 있습니다.
세계적으로 암으로 인한 부담이 지속되고 있는 점이 수요를 뒷받침하고 있습니다. 국제암연구소(IARC)의 보고에 따르면, 2022년에는 전 세계적으로 약 2,000만 건의 신규 암 환자와 970만 건의 암 사망 사례가 확인되었으며, 이로 인해 정확한 조직 진단의 필요성이 부각되고 있습니다. 유방암의 경우, IHC를 바탕으로 한 에스트로겐 수용체, 프로게스테론 수용체 및 HER2 검사가 임상적 판단의 지침이 됩니다. 또한, 폐암, 위암, 요로상피암, 자궁경부암 및 기타 암의 경우, PD-L1 및 미스매치 복구 단백질의 평가가 면역요법 적응증 판단에 있어 점점 더 중요한 역할을 하고 있습니다. 이처럼 암 치료, 동반 진단, 디지털 병리학이 융합되는 가운데, 면역조직화학의 생태계는 지속적인 전략적 투자의 대상으로 자리매김하고 있습니다.
IHC 분야의 혁신적인 변화
IHC 분야는 단순한 염색 워크플로우에서 자동 염색 플랫폼, 검증된 항체 포트폴리오, 영상 관리, 검사 정보 시스템, 품질 보증 프로그램을 결합한 통합적인 진단 생태계로 전환되고 있습니다. 종양학, 신경병리학, 감염증, 염증성 질환 분야에서 바이오마커의 복잡성이 증가함에 따라, 검사 기관들은 재현성, 검사 소요 시간 및 규제 준수를 최우선 과제로 삼고 있습니다.
인공지능(AI)의 누적 영향
인공지능(AI)은 정량화, 일관성 및 워크플로우의 우선순위 설정을 개선함으로써 면역조직화학 분야에서 점차 누적 영향력을 발휘하고 있습니다. AI를 활용한 영상 분석은 막, 핵, 세포질의 바이오마커 점수 산정을 지원하며, Ki-67, ER, PR, HER2, PD-L1 및 종양 침윤 림프구의 평가와 같은 검사에서 검사실이 관찰자 간 변동을 관리하는 데 도움을 줍니다. 이러한 도구는 병리 전문의를 대체하는 것이 아니라, 임상적 검증, 거버넌스 및 품질 관리가 필요한 의사결정 지원 시스템으로서 기능합니다.
지역별 주요 인사이트
북미는 선진적인 병리 인프라, 풍부한 종양학 연구 자금, 정평이 나 있는 동반 진단, 그리고 자동 염색 및 디지털 병리 플랫폼의 고도화된 활용을 통해 IHC 도입을 주도하고 있습니다. 미국은 통합 암 센터, 참조 실험실, 제약사의 바이오마커 프로그램을 통해 임상적·상업적 모멘텀을 주도하고 있는 반면, 캐나다는 체계적인 암 의료 네트워크, 학술 병리학의 탁월성, 그리고 공공 기관이 조정하는 종양학 서비스의 혜택을 누리고 있습니다.
주요 그룹별 인사이트
아세안(ASEAN) 지역에서 면역조직화학의 성장은 싱가포르, 태국, 말레이시아, 인도네시아, 베트남, 필리핀의 병원 네트워크 확대, 의료 관광, 그리고 암 진단 능력 향상과 관련이 있습니다. 싱가포르는 첨단 병리학, 임상시험, 분자진단의 지역적 기준 거점으로서의 역할을 수행하고 있는 반면, 아세안(ASEAN) 주요국에서는 도시 지역의 3차 의료기관 및 민간 검사 기관 네트워크를 통해 자동화된 조직 진단에 대한 접근성이 확대되고 있습니다.
주요 국가에 대한 인사이트
미국은 암 검사 건수가 많고, FDA 승인을 받은 동반 진단, 광범위한 기준 검사실 네트워크, 학술적 암 센터, 그리고 대형 제약사의 바이오마커 프로그램 덕분에 가장 영향력 있는 IHC 시장으로 자리매김하고 있습니다. 캐나다는 탄탄한 학술적 병리학, 공공 기관이 주관하는 암 의료 서비스, 그리고 디지털 병리학의 도입 확대를 통해 그 뒤를 잇고 있습니다. 멕시코와 브라질은 민간 진단 기관, 3차 의료 기관 및 종양학 바이오마커 검사에 대한 수요를 통해 발전하고 있으나, 이용 가능 여부는 지불 주체, 지역 및 공공 검사실의 역량에 따라 달라질 수 있습니다.
업계 리더를 위한 실천적인 제안
업계 리더는 임상적으로 검증된 항체 포트폴리오, 자동화 워크플로우와의 호환성, 그리고 다양한 조직 검체에서 입증된 분석 성능을 우선시해야 합니다. IHC가 치료법 선택과 더욱 밀접하게 연계됨에 따라, 공급업체는 품질 보증, 로트 간 균일성, 규제 관련 문서, 그리고 병리 전문의를 대상으로 한 교육에 투자해야 합니다.
조사 방법
본 요약본은 시장 정보의 모범 사례에 부합하는 체계적인 2차 조사 방식을 통해 작성되었습니다. 조사의 근거가 되는 정보에는 국제 보건 기구, 암 등록 기관, 규제 당국, 임상 지침, 동료 심사를 거친 병리학 문헌, 의료 인프라 지표, 그리고 일반에 공개된 제품 및 기술 문서에서 얻은 정보가 포함됩니다.
결론
면역조직화학은 현대 병리학의 핵심 기술로 자리매김하고 있으며, 정밀 종양학, 동반 진단, 신약 개발, 디지털 병리학 분야에서 그 중요성이 점점 더 커지고 있습니다. 암 발병률 증가, 바이오마커 활용 확대, 재현성 있는 조직 기반 증거에 대한 수요 증가로 인해 성숙 시장과 신흥 시장을 막론하고 수요가 확대되고 있습니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향(2026년)
제7장 면역조직화학 시장 : 제품 카테고리별
제8장 면역조직화학 시장 : 기술별
제9장 면역조직화학 시장 : 검체 유형별
제10장 면역조직화학 시장 : 용도별
제11장 면역조직화학 시장 : 적응증별
제12장 면역조직화학 시장 : 최종 사용자별
제13장 면역조직화학 시장 : 지역별
제14장 면역조직화학 시장 : 그룹별
제15장 면역조직화학 시장 : 국가별
제16장 경쟁 구도
제17장 기업 개요
KTH 26.07.24The Immunohistochemistry Market is projected to grow by USD 5.07 billion at a CAGR of 6.16% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 3.33 billion |
| Estimated Year [2026] | USD 3.53 billion |
| Forecast Year [2032] | USD 5.07 billion |
| CAGR (%) | 6.16% |
Immunohistochemistry (IHC) remains a core technology in tissue-based diagnostics, translational research, and precision oncology because it localizes protein expression within preserved cellular architecture. In routine pathology, IHC supports tumor classification, biomarker confirmation, infectious disease evaluation, autoimmune pathology, and therapy selection, making it indispensable to hospital laboratories, reference laboratories, pharmaceutical developers, and contract research organizations.
Demand is reinforced by the sustained global cancer burden. The International Agency for Research on Cancer reported approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, underscoring the need for accurate tissue diagnostics. In breast cancer, IHC-based estrogen receptor, progesterone receptor, and HER2 testing guides clinical decision-making; in lung, gastric, urothelial, cervical, and other cancers, PD-L1 and mismatch repair protein evaluation increasingly inform immunotherapy eligibility. This convergence of oncology care, companion diagnostics, and digital pathology is positioning the immunohistochemistry ecosystem for continued strategic investment.
Transformative Shifts in the IHC Landscape
The IHC landscape is shifting from standalone staining workflows toward integrated diagnostic ecosystems that combine automated staining platforms, validated antibody portfolios, image management, laboratory information systems, and quality assurance programs. Laboratories are prioritizing reproducibility, turnaround time, and regulatory compliance as biomarker complexity increases across oncology, neuropathology, infectious disease, and inflammatory disorders.
A major transformation is the rise of companion diagnostics and therapy-linked biomarkers. Regulatory-approved IHC assays for targets such as HER2, PD-L1, ALK, and mismatch repair proteins have increased the strategic importance of assay validation, pre-analytical control, and pathologist training. At the same time, multiplex IHC and spatial biology approaches are expanding the ability to evaluate immune contexture, tumor microenvironment, and co-expression patterns, supporting both clinical trial enrichment and drug development programs.
Operationally, automation is reshaping procurement decisions. High-throughput staining systems, standardized antigen retrieval, ready-to-use antibodies, and digital slide review reduce variability across institutions. These changes favor suppliers that can provide end-to-end workflow reliability, robust technical support, and evidence-based assay performance across diverse tissue types.
Cumulative Impact of Artificial Intelligence
Artificial intelligence is becoming a cumulative force in immunohistochemistry by improving quantification, consistency, and workflow prioritization. AI-assisted image analysis can support scoring of membrane, nuclear, and cytoplasmic biomarkers, helping laboratories manage interobserver variability in assays such as Ki-67, ER, PR, HER2, PD-L1, and tumor-infiltrating lymphocyte assessment. These tools do not replace the pathologist; they function as decision-support systems that require clinical validation, governance, and quality control.
The impact is strongest when AI is paired with whole-slide imaging and standardized staining. Digital pathology adoption has accelerated in leading health systems and pharmaceutical research settings, while regulators in major markets increasingly expect transparent validation, performance documentation, and human oversight. In drug development, AI-enabled IHC analysis can improve patient stratification, quantify biomarker heterogeneity, and generate reproducible endpoints for clinical trials.
However, adoption depends on data quality, scanner compatibility, algorithm generalizability, cybersecurity, and reimbursement clarity. Industry leaders that build interoperable, explainable, and clinically validated AI workflows will be best positioned to convert digital pathology investments into measurable diagnostic and research value.
Key Regional Insights
North America leads IHC adoption through advanced pathology infrastructure, strong oncology research funding, recognized companion diagnostics, and high utilization of automated staining and digital pathology platforms. The United States drives clinical and commercial momentum through integrated cancer centers, reference laboratories, and pharmaceutical biomarker programs, while Canada benefits from organized cancer care networks, academic pathology excellence, and publicly coordinated oncology services.
Europe demonstrates mature immunohistochemistry utilization, supported by national healthcare systems, European Union regulatory harmonization, external quality assessment programs, and strong pathology research in Germany, France, Italy, Spain, and the United Kingdom. The region's focus on quality assurance, CE-marked diagnostics, and cross-border clinical research strengthens adoption of standardized IHC assays, although implementation may vary by reimbursement, workforce capacity, and laboratory digitization levels.
Asia-Pacific is a fast-evolving regional opportunity as China, India, Japan, South Korea, Australia, and ASEAN markets expand cancer screening, hospital infrastructure, precision medicine initiatives, and access to oncology biomarker testing. Japan and South Korea have highly advanced diagnostic ecosystems, China is scaling IHC across large hospital networks and cancer centers, and India is improving access through private diagnostics and tertiary oncology institutions. Latin America is advancing through Brazil and Mexico, where demand is supported by rising oncology caseloads, private laboratory modernization, and expanding access to biomarker-guided cancer care. The Middle East, particularly GCC countries, is investing in specialty hospitals, cancer centers, and laboratory automation as part of broader health system modernization, while Africa's immunohistochemistry market is emerging through academic medical centers, international health partnerships, cancer registry development, and gradual pathology capacity building.
Key Group Insights
Within ASEAN, immunohistochemistry growth is linked to expanding hospital networks, medical tourism, and increasing cancer diagnostic capacity in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. Singapore serves as a regional reference hub for advanced pathology, clinical trials, and molecular diagnostics, while larger ASEAN countries are scaling access to automated tissue diagnostics in urban tertiary centers and private laboratory networks.
The GCC is investing in oncology care, specialist hospitals, and laboratory modernization as governments prioritize noncommunicable disease management and localized healthcare capacity. These investments support adoption of automated IHC, companion diagnostics, and digital pathology, especially in Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait. The European Union remains a high-value group due to harmonized regulatory expectations, public cancer programs, external quality assessment practices, and strong diagnostic manufacturing and clinical research capabilities.
BRICS countries represent volume-driven expansion, led by China and India with large patient populations, growing oncology infrastructure, and increasing precision medicine adoption, while Brazil, Russia, and South Africa contribute demand through public and private healthcare systems with varying levels of reimbursement and laboratory capacity. G7 markets remain innovation leaders because of established reimbursement pathways, academic cancer centers, validated companion diagnostic use, and pharmaceutical research intensity. NATO-aligned markets, particularly in North America and Europe, benefit from resilient healthcare infrastructure, advanced laboratory networks, biomedical research funding, and shared emphasis on diagnostic quality and health security.
Key Country Insights
The United States is the most influential IHC market due to high cancer testing volume, FDA-approved companion diagnostics, extensive reference laboratory networks, academic cancer centers, and major pharmaceutical biomarker programs. Canada follows with strong academic pathology, publicly organized cancer services, and increasing digital pathology adoption. Mexico and Brazil are advancing through private diagnostics, tertiary hospitals, and demand for oncology biomarker testing, although access can vary by payer, region, and public-sector laboratory capacity.
In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain robust immunohistochemistry utilization through established pathology systems, national cancer strategies, external quality programs, and participation in multicenter clinical trials. Germany benefits from advanced laboratory automation and diagnostics manufacturing capabilities, France has strong translational oncology programs, Italy and Spain show broad clinical uptake across public hospitals, and the United Kingdom is expanding digital pathology through health system modernization initiatives. Russia maintains demand through large hospital networks and oncology programs, though procurement and technology access may be influenced by geopolitical and supply-chain constraints.
In Asia-Pacific, China is scaling IHC through large tertiary hospitals, cancer centers, and domestic diagnostics development. India is expanding through private laboratory chains, oncology hospitals, medical education initiatives, and growing awareness of biomarker-driven treatment. Japan remains highly advanced in precision diagnostics, quality assurance, and oncology drug development, while South Korea combines strong hospital infrastructure with rapid digital health adoption and clinical research activity. Australia benefits from high diagnostic standards, national cancer care initiatives, external quality assessment participation, and early adoption of digital pathology in select networks.
Actionable Recommendations for Industry Leaders
Industry leaders should prioritize clinically validated antibody portfolios, automated workflow compatibility, and evidence-backed assay performance across diverse tissue specimens. As IHC becomes more tightly linked to treatment selection, suppliers must invest in quality assurance, lot-to-lot consistency, regulatory documentation, and pathologist education.
Laboratories should standardize pre-analytical processes, including fixation time, tissue processing, antigen retrieval, and scoring protocols, to reduce variability. Health systems can improve turnaround time and diagnostic confidence by integrating automated staining, digital slide management, and validated AI-assisted quantification where appropriate.
Pharmaceutical and diagnostics organizations should expand co-development strategies for companion diagnostics, particularly in immuno-oncology, breast cancer, gastrointestinal cancers, lung cancer, and emerging spatial biology applications. In high-growth markets, success will depend on local technical support, reagent affordability, training programs, and partnerships with cancer centers and reference laboratories.
Research Methodology
This executive summary is developed using a structured secondary research approach aligned with market intelligence best practices. Inputs include publicly available information from international health agencies, cancer registries, regulatory bodies, clinical guidelines, peer-reviewed pathology literature, healthcare infrastructure indicators, and publicly accessible product and technical documentation.
The analysis emphasizes verified trends rather than speculative claims. Regional and country-level interpretations are derived from observable healthcare capacity, oncology burden, regulatory maturity, diagnostic adoption patterns, quality assurance practices, and the presence of academic, hospital, and reference laboratory networks. Insights are synthesized to support strategic decision-making for manufacturers, laboratories, healthcare providers, pharmaceutical organizations, and investors in the immunohistochemistry ecosystem.
Conclusion
Immunohistochemistry continues to be a foundational technology for modern pathology, with expanding relevance in precision oncology, companion diagnostics, drug development, and digital pathology. Rising cancer incidence, broader biomarker utilization, and the need for reproducible tissue-based evidence are strengthening demand across mature and emerging markets.
The next phase of differentiation will be shaped by automation, validated antibody performance, AI-assisted image analysis, multiplex assays, spatial biology, and integrated diagnostic workflows. Organizations that combine scientific credibility with scalable operations, regulatory readiness, and regional adaptability will be best positioned to capture long-term opportunities in the global IHC ecosystem.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Immunohistochemistry Market, by Product Category
- 7.1. Antibodies
- 7.1.1. Primary Antibodies
- 7.1.1.1. Monoclonal
- 7.1.1.2. Polyclonal
- 7.1.1.3. Recombinant Monoclonal
- 7.1.1.4. Recombinant Fragments
- 7.1.2. Secondary Antibodies
- 7.1.2.1. Enzyme-Conjugated
- 7.1.2.2. Biotinylated
- 7.1.2.3. Fluorophore-Conjugated
- 7.1.2.4. Unconjugated
- 7.1.1. Primary Antibodies
- 7.2. Detection Systems
- 7.2.1. Polymer
- 7.2.2. Avidin-Biotin
- 7.2.3. Tyramide Amplification
- 7.3. Chromogens & Counterstains
- 7.3.1. DAB
- 7.3.2. AEC
- 7.3.3. Fast Red
- 7.3.4. Hematoxylin
- 7.4. Ancillary Reagents
- 7.4.1. Retrieval Buffers
- 7.4.2. Blocking Reagents
- 7.4.3. Wash Buffers
- 7.5. Kits & Panels
- 7.5.1. Single-Marker Kits
- 7.5.2. Multiplex Panels
8. Immunohistochemistry Market, by Technology
- 8.1. Chromogenic IHC
- 8.1.1. HRP/DAB
- 8.1.2. AP/Red
- 8.1.3. Dual Enzyme
- 8.2. Immunofluorescence
- 8.2.1. Singleplex IF
- 8.2.2. Multiplex IF
- 8.3. Signal Amplification
- 8.3.1. Tyramide Signal Amplification
- 8.3.2. Biotin-Based Amplification
- 8.4. Metal-Conjugated IHC
- 8.4.1. Mass Cytometry-Compatible
- 8.4.2. MIBI-Compatible
9. Immunohistochemistry Market, by Specimen Type
- 9.1. FFPE Tissue
- 9.1.1. Resection
- 9.1.2. Biopsy
- 9.2. Frozen Tissue
- 9.3. Cytology Specimens
- 9.3.1. Smears
- 9.3.2. Liquid-Based Preparations
- 9.4. Tissue Microarrays
10. Immunohistochemistry Market, by Application
- 10.1. Clinical Diagnostics
- 10.1.1. Oncology
- 10.1.1.1. Solid Tumors
- 10.1.1.2. Hematopathology
- 10.1.2. Infectious Disease
- 10.1.3. Transplant Immunopathology
- 10.1.4. Neuropathology
- 10.1.5. Cardiovascular Pathology
- 10.1.6. Companion Diagnostics
- 10.1.1. Oncology
- 10.2. Research & Drug Discovery
- 10.2.1. Basic Research
- 10.2.2. Translational Research
- 10.2.3. Target Validation
- 10.2.4. Biomarker Discovery
- 10.2.5. Toxicologic Pathology
- 10.3. Veterinary Pathology
- 10.4. Forensic Pathology
- 10.5. Education & Training
11. Immunohistochemistry Market, by Indication
- 11.1. Oncology
- 11.1.1. Breast Cancer
- 11.1.2. Lung Cancer
- 11.1.3. Colorectal Cancer
- 11.1.4. Prostate Cancer
- 11.1.5. Melanoma
- 11.1.6. Lymphoma
- 11.1.7. Brain Tumors
- 11.2. Infectious Diseases
- 11.2.1. Viral
- 11.2.2. Bacterial
- 11.2.3. Fungal
- 11.3. Autoimmune & Inflammatory
- 11.3.1. Systemic Autoimmune
- 11.3.2. Gastrointestinal Inflammatory
- 11.4. Neurological Disorders
- 11.5. Renal & Hepatic
- 11.5.1. Renal Disease
- 11.5.2. Hepatic Disease
12. Immunohistochemistry Market, by End User
- 12.1. Hospital Laboratories
- 12.1.1. Community Hospitals
- 12.1.2. Academic Medical Centers
- 12.2. Reference Laboratories
- 12.3. Academic & Research Institutes
- 12.4. Pharmaceutical & Biotechnology
- 12.4.1. In-House Labs
- 12.4.2. Outsourced Partners
- 12.5. Contract Research Organizations
- 12.6. Veterinary Pathology Laboratories
13. Immunohistochemistry Market, by Region
- 13.1. Asia-Pacific
- 13.2. North America
- 13.3. Latin America
- 13.4. Europe
- 13.5. Middle East
- 13.6. Africa
14. Immunohistochemistry Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
15. Immunohistochemistry Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
16. Competitive Landscape
- 16.1. Market Concentration Analysis, 2025
- 16.1.1. Concentration Ratio (CR)
- 16.1.2. Herfindahl Hirschman Index (HHI)
- 16.2. Recent Developments & Impact Analysis, 2025
- 16.3. Product Portfolio Analysis, 2025
- 16.4. Benchmarking Analysis, 2025
17. Company Profiles
- 17.1. Agilent Technologies Inc.
- 17.2. Becton, Dickinson & Company
- 17.3. Bio SB
- 17.4. Bio-Rad Laboratories Inc.
- 17.5. Bio-Techne Corporation
- 17.6. Biocare Medical LLC
- 17.7. Biogenex Laboratories
- 17.8. CANDOR Bioscience GmbH
- 17.9. Cell Signaling Technology, Inc.
- 17.10. Danaher Corporation
- 17.11. Diagnostic BioSystems Inc.
- 17.12. Eagle Biosciences, Inc.
- 17.13. Elabscience Biotechnology Inc.
- 17.14. F. Hoffman-La Roche AG
- 17.15. Genemed Biotechnologies, Inc. =
- 17.16. Histo-Line Laboratories
- 17.17. Lunaphore Technologies SA
- 17.18. Merck KGaA
- 17.19. Miltenyi Biotec B.V. & Co. KG
- 17.20. PerkinElmer Inc.
- 17.21. Rockland Immunochemicals, Inc.
- 17.22. Takara Bio, Inc
- 17.23. Thermofisher Scientific, Inc.
